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Background: Malaria in Cameroon is due to infections by Plasmodium falciparum and, to a lesser extent,
Plasmodium malariae and Plasmodium ovale, but rarely Plasmodium vivax. A recent report suggested “Plasmodium
vivax–like” infections around the study area that remained unconfirmed. Therefore, molecular and antigenic typing
was used to investigate the prevalence of P. vivax and Duffy in asymptomatic adults resident in Bolifamba.
Methods: A cross-sectional study was conducted from July 2008 to October 2009. The status of all parasite species
was determined by nested PCR in 269 blood samples collected. The P. falciparum and P. vivax anti-MSP/CSP
antibody status of each subject was also determined qualitatively by a rapid card assay. Parasite DNA was extracted
from a sample infected with three parasite species, purified and sequenced. The Duffy antigen status of 12 subjects
infected with P. vivax was also determined by sequencing. In silico web-based tools were used to analyse sequence
data for similarities and matches to reference sequences in public DNA databases.
Results: The overall malaria parasite prevalence in 269 individuals was 32.3% (87) as determined by PCR.
Remarkably, 14.9% (13/87) of infections were caused either exclusively or concomitantly by P. vivax, established
both by PCR and microscopic examination of blood smears, in individuals both positive (50%, 6/12) and negative
(50%, 6/12) for the Duffy receptor. A triple infection by P. falciparum, P. vivax and P. malariae, was detected in one
infected individual. Anti-MSP/CSP antibodies were detected in 72.1% (194/269) of samples, indicating high and
continuous exposure to infection through mosquito bites.
Discussion: These data provide the first molecular evidence of P. vivax in Duffy positive and negative
Cameroonians and suggest that there may be a significant prevalence of P. vivax infection than expected in the
study area. Whether the P. vivax cases were imported or due to expansion of a founder effect was not investigated.
Notwithstanding, the presence of P. vivax may complicate control efforts if these parasites become hypnozoitic or
latent as the liver stage.
Conclusions: These data strongly suggest that P. vivax is endemic to the south-west region of Cameroon and
should be taken into account when designing malaria control strategies.
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Malaria is now second to HIV/AIDS as the global cause
of death from infectious diseases, but remains the main
global cause of death from parasitic infectious diseases
[1]. Malaria threatens approximately half the world’s
population and causes debilitating illness in more than
half a billion people. Morbidity and mortality is particu-
larly high in sub-Saharan Africa, where children below
five years are at greatest risk of infection, clinical disease
and death [1,2]. Yet malaria control strategies have been
productive: in 2010, the World Health Organization
(WHO) estimated 660,000 deaths due to malaria, indicat-
ing a drop of 25% globally and 33% in the WHO African
Region since 2000 [1]. Plasmodium falciparum remains
the deadliest of the malaria parasite species in Africa [1]
and also wreaks significant economic havoc in highly en-
demic areas, substantially decreasing gross domestic prod-
uct (GDP) of affected countries relative to malaria-free
regions [3,4].
With decreases in the falciparum burden, attention
must also be focused on more than four hundred million
malaria cases due to other parasite species [5], namely
Plasmodium vivax, Plasmodium malariae, Plasmodium
ovale and, more recently, Plasmodium knowlesi (a simian
malaria parasite responsible for a zoonotic form of malaria
in humans). Plasmodium vivax is fast becoming a recog-
nized cause of different grades of malaria pathologies on
the African continent [6-19], infecting both children and
adults, thus threatening the prospect of malaria elimin-
ation in parts of Africa. In particular, elimination of
asymptomatic malaria is critical for eradication.
There have been two documented reports of infections
ascribed to P. vivax in Cameroon [14,18]. These reports
were not in subjects of African origin, but in non-
Cameroonians who had lived in Cameroon previously
and had returned to their home countries several years
before the diagnosis indicating asymptomatic carriage.
Additionally in 2005, Kimbi and colleagues [20] reported
P. vivax-like asymptomatic infections in Cameroonian
school children with a prevalence of up to 33.3%, but
this was diagnosed only by light microscopy. The resear-
chers were not very certain about speciation or species
identification capabilities, and thus referred to it as “P.
vivax -like” asymptomatic infection. This was also due to
the notion that Africans for a long time were considered
to be refractory to P. vivax infection [21], because they
lack the Duffy antigen, a receptor needed for P. vivax to
attach to and invade red blood cells. Unfortunately, there
was no follow up on the “P. vivax-like” finding and thus
there are no conclusive data on the presence of P. vivax
infections in Cameroon.
Data on the prevalence of Duffy antigen in Cameroonians
is also absent. In a bid to bridge this gap in knowledge, the
present cross-sectional study was conducted with an aim todetect Plasmodium species and the Duffy status of asymp-
tomatically infected adults. This group is an increasingly
important pool for identifying malaria parasite species that
remain prevalent in the population even as the burden of
febrile (mostly P. falciparum) infections is systematically
reduced. The participants were resident in Bolifamba, a




This study was authorized by the South West Regional
Delegate of Public Health and the University of Buea
Institutional Review Board. All subjects gave signed infor-
med consent before enrollment into the study. All proto-
cols involving human subjects were approved by the IRB
of the University of Notre Dame.
Study area
The study was carried out in Bolifamba, a multi-ethnic
rural setting [22] 530 m above sea level situated on the
east slope of Mount Cameroon in the South West Region.
Although malaria is endemic throughout Cameroon [23],
the country has very different geographical and epidemio-
logic levels [24]. The epidemiology of malaria in Bolifamba
has been well described [22]. Malaria transmission occurs
all year round, with peak transmissions during the peak
rainy months (July and August). There are two seasons in
Bolifamba: the rainy season that runs from March to
October and the dry season from November to February.
The prevalence of malaria parasitaemia in this area ranges
from 30% in the dry season to 65% in the rainy season
[25]. Plasmodium falciparum accounts for up to 96% of
malaria infections in this area [26], with Anopheles gam-
biae s.s. being the dominant vector [27]. Hydrologically, a
stream runs through the village and is of prime import-
ance to the villagers and to the epidemiology of the
disease. In this forested area of Southern Cameroon, the
equatorial climate has been modified by the double in-
fluence of the ocean and the mountain. The average
humidity is constantly high, between 75-80% or more and
temperatures are lower than in the other areas of the
southern part of the country; the mean values of the mini-
mum temperatures are 20°C in December and 18°C in
August, the mean values of the maximum temperatures
are 35°C in August and 30°C in March. Notwithstanding,
seasons in Mt. Cameroon region have become quite vari-
able in the past decade, with rains beginning in June and
lasting until early November, causing some variability in
malaria prevalence and transmission patterns [28]. The
mountain starts at an altitude of about 50 m from the
coast as a sedimentary plain that extends from Limbe to
Mutengene and Tiko. From Mutengene, the terrain grad-
ually elevates to an altitude of 800–1200 m in Buea town
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garden and zoo and other recreational sites in Limbe
attract tourists of various nationalities. This makes the
populations along the Mount Cameroon area highly
cosmopolitan. The indigenous inhabitants of Bolifamba
are of several ethnic groups [22] and the main occupation
is farming. Farm lands extend to the forest areas. By 2005,
the population of Bolifamba was assessed to be about
3,500 inhabitants [22].
Study group/study period
The study group consisted of apparently healthy adults
resident in Bolifamba and aged 18–55 years. The sub-
jects had lived in the area for at least five consecutive
years. Subjects with signs and symptoms of any chronic
illness were not included in the study.
Sample collection
A door-to-door visit of randomly selected houses was
carried out in all the quarters of the Bolifamba village.
All participants were non febrile (body temperature
below 37.5°C) at time of blood draw. A brief history of
malaria infection and management habits was recorded
for each subject. Five mL of blood was collected by
venipuncture from each of the 269 subjects enrolled
into EDTA containing tubes during the (peak) rainy
malaria transmission months throughout the study period
(July 2008 to October 2009). The blood was separated
into plasma and red cell components by spinning in a
Beckmann® centrifuge (Beckmann®, State Technology Inc,
Bridgeport NJ, USA) at 2500 rpm for 5 min.
Parasitological examination
Thick and thin blood smears were prepared from a small
portion of whole blood of each subject on the same slide
according the methods previously described [30-32]. The
thin blood smears were methanol-fixed and both smears
stained with Giemsa stain and examined under the oil
immersion lens (x100) and x10 eye piece of an Olympus®
light microscope. Parasitaemia was evaluated as previously
described [31]. Essentially, with each positive smear,
the level of parasitaemia was estimated by counting
the parasites against at least 200 leucocytes and then
using the leucocyte (WBC) count to estimate the
number of parasites/μL of whole blood while assuming an
average of 8,000 WBCs/μL of whole blood as shown in
equation 1.
Parasite Density ¼ Number of Parasite Counted
Number of WBCs
 WBC 800 cellsð Þ per μl Blood:
ð1ÞAnti MSP/CSP antibody card assay
As a measure of exposure of the subjects to malaria
(through infective bites of mosquitoes), the antibody
status of each subject was assessed qualitatively by a
rapid immunochromatographic card assay detecting either
antibodies to the merozoite surface protein (MSP) or the
circumsporozoite protein (CSP) (International Immuno-
Diagnostics, CA, USA). The assay was carried out as
described by the kit manufacturers (International Immuno-
Diagnostics, CA, USA). Briefly, 10 μL of plasma sample
was added to a sample well and 3 drops of the supplied
assay diluent added immediately to the same sample well
and then allowed to migrate by capillary action. Results
were interpreted within 10–20 minutes of adding plasma
and assay diluent. The appearance of a visible band corre-
sponded to plasma reactivity with either P. falciparum or
P. vivax antigens, or both. An additional control band
always appeared as an internal control to enable validation
of assay results and/or to ascertain that the test card was
not faulty in production. When no internal control band
was seen, even when the test band(s) appeared, the assay
result was discarded and repeated using a fresh card.
Nested polymerase chain reaction (PCR)
Plasmodium speciation was done for all the 269 subjects
using the Nested Polymerase Chain Reaction (PCR)
method described by Kimura et al., [33] with some mod-
ifications. The Phusion® blood PCR kit was used for the
Nest 1 reaction. This enabled the amplification of parasite
DNA directly from 0.003% of frozen packed red cells. All
PCRs were carried out in a total volume of 20 μL. The
reaction mixture had final concentrations of MgCl2
(3.0 mM), 200 μM of each dNTP, 0.25 pmol/μL of each
primer, 2.5 mM EDTA, 5% DMSO, 0.4 U Phusion Blood
II DNA Polymerase. The cycling parameters for the Nest
1 reaction using the PTC-100 programmable thermal
cycler (MJ. Research Inc., Waltham. MA, USA) were as
follows: 1) Lysis of cells/initial denaturation 98°C for 5 mi-
nutes; 2) Denaturation at 98°C for 1 sec; 3) Annealing at
72°C for 15 sec; 4) Extension 72°C for 30 sec; 5) Repeat
steps 2–4 for a total of 35 times; 6) Final annealing at
72°C for 10 minutes and 7) 4°C indefinitely.
For the Nest 2 reaction the TaKaRa kit (TaKaRa Ex
Taq™, Hot Start Version) with the high fidelity HS Taq
polymerase was used instead of the Phusion® blood kit.
All PCRs were also carried out in a total volume of
20 μL. The reaction mixture had final concentrations of
MgCl2 (2.005 mM), 150 μM of each dNTP, 0.25 pmol/
μL of each primer, 0.05 U Taq HS DNA Polymerase.
Two micro liters of a 1:50 dilution of the Nest 1 ampli-
con in MiliQ water (MiliQ system) was used as template
in the Nest 2 reaction. The cycling parameters for the
Nest 2 reaction using the PTC-100 programmable ther-
mal cycler (MJ. Research Inc., Waltham. MA, USA) were
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Denaturation at 98°C for 1 sec; 3) Annealing at 60°C for
15 sec; 4) Extension 60°C for 30 sec; 5) Repeat steps 2–4
for a total of 18 times; 6) Final annealing at 60°C for
10 minutes and 7) 4°C indefinitely. The sequence of
oligonucleotides used in both the NEST 1 and 2 reactions
were as previously published [6,33].
Analysis of the amplified gene products
The Nest 2 amplicon was separated on a 2% agarose gel
and a gel picture taken under UV light. All buffers and gel
preparations were as described by Sambrook et al. [34].
Purification and quantification of amplified DNA
The malaria parasite species bands were extracted from
the gel for one subject with triple infection and purified
using the QIAquick Gel Extraction Kit essentially as
described by the manufacturer (Qiagen®). Five (5) μL of
the purified DNA was run on a 2% agarose gel to ascertain
purity and for semi-quantification.
Sequencing/genotyping of the purified parasite DNA and
DARC gene promoter DNA fragment
A sequencing order for all DNA to be sequenced was
submitted (on line) to the sequencing and genotyping
facility of the University of Chicago cancer center [35]
and the appropriately labeled samples sent to the facility
by postal mail service.
Bioinformatics (in silico) analyses of the sequenced
parasite DNA
The finished sequences were downloaded from the Uni-
versity of Chicago comprehensive cancer center web page
[36], cleaned and used in a BLASTn algorithm against the
GenBank reference genomic sequence of Plasmodium
available at the NCBI web page [37] and the output file
showing the hits and similarity profile copied and saved.
Duffy blood group determination
To detect the point mutation -33 T→C, which corre-
sponds to a Duffy-negative phenotype, the DARC gene
promoter region of 13 subjects were amplified directly
from frozen packed red and white cells by PCR, followed
by wet lab enzymatic restriction digestion with StyI
(New England Biolabs, Ipswich, MA), as well as in silico
StyI enzymatic restriction digestion.
The PCR was done with primer pairs previously pub-
lished [6] with a slight modification of the PCR constitu-
ents. The 224 bp fragment was amplified directly from
diluted packed red cells or neat plasma using the Direct
PCR Blood Phusion® kit (Thermo Scientific) according
to the manufacturer’s instructions. All reactions were
carried out in a total volume of 20 μL. The reaction mix-
ture had final concentrations of MgCl2 (3.0 mM), 200 μMof each dNTP, 0.25 pmol/μL of each primer, 2.5 mM
EDTA, 3% DMSO, 0.4 U Phusion Blood II DNA Poly-
merase and 0.5 μL of 0.001% packed red cells. The cycling
parameters using the PTC-100 programmable thermal
cycler (MJ. Research Inc., Waltham. MA, USA) were as
follows; Lyses of cells/initial denaturation 98°C for 5 mi-
nutes, Denaturation at 98°C for 1 sec, Annealing at 59°C
for 15 sec, Extension 72°C for 30 sec, Repeat steps 2–4 for
a total of 35 times, final annealing at 72°C for 10 minutes
and 4°C forever.
Analysis of the amplified gene products
The amplicons were separated on a 2% agarose gel along-
side a 100 bp DNA ladder and the gel photographed
under UV light. All buffers and gel preparations were as
described by Sambrook et al. [34].
Purification and quantification of the amplified 224 bp
DARC gene promoter DNA fragment
The 224 bp band corresponding to the DARC gene pro-
moter fragment was extracted from the gel and purified
using the QIAquick Gel Extraction Kit essentially as
described by the manufacturer (Qiagen®). Five μL of the
purified DNA was run on a 2% agarose gel to ascertain
purity and for semi-quantification.
Bioinformatics (in silico) analyses of the sequenced DARC
gene promoter fragment
The sequences were downloaded from the University of
Chicago comprehensive cancer center web page [36],
cleaned and used in a multiple sequence alignment of
the 12 subjects’ DARC gene promoter sequences on the
NCBI web site against the DARC gene promoter Duffy
positive consensus sequence downloaded from the NCBI
web page. The output file showing the alignment profile
was copied and saved.
Wet lab StyI restriction digestion of the amplified DARC
gene promoter fragment
In order to assess by another means whether the frag-
ments amplified from the various subjects contained the
sought T→C point mutation that confers the Duffy
negative phenotype, a portion of the gel purified DNA
was digested with the enzyme StyI, (New England Biolabs,
NEB labs). This enzyme will cut the 224 bp fragment at 2
recognition sites to produce 3 restriction fragments of
sizes 82, 77 and 64 bp, for Duffy positive genotypes or will
cut at 3 recognition sites, producing 4 restriction frag-
ments of sizes 82, 65, 64 and 12 bp, if the subject is Duffy
negative. In Duffy negative subjects, the point mutation in
the DARC promoter gene segment creates an additional
restriction site for StyI in the 77 bp fragment, breaking it
into the 65 and 12 bp fragments.
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the kit manufacturer’s instructions. Briefly, 10 μL of each
purified DNA was used in the restriction mixture com-
prising 5 μL of miliQ water, 2 μL of 10X Bovine serum
albumin (BSA), 2 μL of 10X NEBuffer 3, and 1 μL of StyI
enzyme. The 20 μL total restriction volume in a 1.5 mL
eppendorf tube was incubated in pre-heated water in the
wells of a heating block at 37°C for at least 1 hour. The
entire 20 μL tube content for each subject was mixed
with 5 μL of 6x Orange G DNA loading dye (Sigma) and
loaded onto a 20% DNA polyacrylamide gel (prepared as
described by Sambrook et al. [34]), along with a 100 bp
DNA ladder (Promega). The gel was run at 50 V for
3 hours. The bands were visualized under UV light on a
Trans-illuminator.
In silico StyI restriction digestion of the DARC promoter
sequences
Given that the wet lab separation of the restriction prod-
uct of the 20% native DNA PAG could be very dubious,
the full DARC promoter sequence of each subject was
subjected to in silico restriction digestion with the same
enzyme (StyI) that was used in the wet lab analysis in
order to confirm or refute the more convincing sequence
alignment profile relative to the restriction electrophore-
graph. This was done using NEBcutter 2 software freely
available on the web. Each subject’s full length amplified
DARC DNA sequence was interrogated with in silico StyI
restriction enzyme and the restriction map showing num-
ber of restriction sites copied.
Statistical analyses
The data were analysed using the Statistical Package for
Social Sciences (SPSS) version 17.0 (Chicago, IL USA),
and the Microsoft Excel 2010 (Microsoft Corporation).
The Chi-Square test and the Pearson’s correlation were
used to find correlation between categorical and numeric
variables respectively. Statistical significance was set at
p ≤ 0.05. Multiple sequence alignments were done using
freely available web-based ClustalW software. The free
web based NEBCutter 2 software was also available for in
silico enzymatic restriction digestion. Sequences for ana-
lyses were either reversed or reverse complemented using
free web-based softwares. Reference sequences were
downloaded from respective public databases.
Results
Detection of Plasmodium vivax and Plasmodium
falciparum infection by Giemsa
Representative examples of thin films positive by Giemsa
staining confirmed malarial infection suggestive of P.
falciparum as well as other species (see Figure 1). Unfor-
tunately, some of the morphologies shown in Figure 1 do
not show hallmark characteristics of any species. Figure 1B and C are not likely to be P. falciparum because they
are trophozoite stage parasites and schizont stages seen in
peripheral circulation. Figure 1 D does show a characteris-
tic P. falciparum ring, but convincing speciation required
additional analyses.Detection of anti-parasite antibodies to P. vivax and
P. falciparum in asymptomatic subjects
To determine whether P. vivax was present in our sam-
ples, at first pass they were examined using antigens that
will bind to both P. vivax and P. falciparum specific anti-
bodies. This was done using qualitative anti-MSP/CSP
antibody immunochromatographic card tests that distin-
guish between antibodies to both the MSP/CSP of P. fal-
ciparum and P. vivax. Based on this anti MSP/CSP
antibody card assay, the overall prevalence of malaria
exposure was 72.1% (194/269). The prevalence of single
and mixed Plasmodium antibodies is shown on Table 1.
The vast majority (66%) of samples indicated exposure to
P. falciparum alone, ~1% exposure to P. vivax and about
4% exposure to both.Detection of malaria species in asymptomatic subjects by
nested PCR
Since P. malariae can also be found in Cameroon but
not detected by the antigen kit, PCR analysis was used
for definitive analysis on speciation (Figure 2). Of 269
samples collected, 66 were positive for P. falciparum
(Table 2). Notably nine were positive for P vivax, four
were positive for P. malariae and none contained P.
ovale alone. Three were double positive P. vivax and
P. falciparum another four showed both P. malariae
and falciparum. One was triply positive for P. malariae,
P. falciparum and P. vivax and here the primary data
are shown in Figure 2. These bands were isolated and
sequenced to confirm the simultaneous presence of
all three species based on similarity scores (Figure 3).
Although parasite morphology on the P. vivax positive
smears (Figure 1, Panels A-C) did not all show landmark
features of P. vivax-infected erythrocytes, the fact that
they were read from slides that were solely positive
for P. vivax by PCR was a confirmation that the para-
sites seen were indeed P. vivax. In Figure 1, Panel D shows
a typical Pf ring from a sample that was PCR positive for
just P. falciparum.
BLASTn analyses of the DNA sequences generated
from the sample with triple bands on Figure 2 confirmed
that the P. falciparum, P. vivax and P. malariae bands
matched the Genbank P. falciparum isolate SF4 18S ribo-
somal RNA gene partial sequence ID: gb│JQ627152.1│, P.
vivax isolate SV6 18S ribosomal RNA gene partial
sequence ID: gb│JQ627158_1│, and P. malariae type 2




Figure 1 Parasites images (arrow heads) from Pv positive (panels A-C) and Pf positive (panel D) slides. Panel A shows a young
trophozoite or late ring stage parasite in an intact red cell. Panel B shows a late stage P. vivax (Pv) trophozoite in an intact red blood cell. Panel C
shows a schizont out of the red cell that does not look healthy. Panel D shows a typical P. falciparum (Pf) ring-stage parasite with double chromatin
dots and pale blue cytoplasm. Scale bars = 10 μm).
Fru-Cho et al. Malaria Journal 2014, 13:170 Page 6 of 11
http://www.malariajournal.com/content/13/1/170ID: gb│AF488000.1│ by 100%, 97%, and 100% respec-
tively (Figure 3).
Overall there were as many as 87 infected of a total of
269 participants, suggesting as many as a third of asymp-
tomatic patients at this site may contain parasite reser-
voirs. There were many cases where the subjects were
positive for parasite by PCR but negative for anti-MSP/
CSP antibodies (9.3%, 25/269). This may be due to very
low levels of both P. falciparum and P. vivax infection and
suggests that almost a third of the P. vivax infections are
truly asymptomatic in absence of an antibody response.Table 1 Distribution of malarial species detected by the card
P. falciparum P. vivax
Percent fraction of total samples
shown in parenthesis*
Percent fraction of total samples shown
180 (66.9) 3 (1.1)
*Total number of subjects (269).
Table 1 shows the numbers of samples (and the percent fraction of total samples) s
total of 269 samples were subjected to the Card test (see Methods).Duffy antigen typing
Having recoded a number of P. vivax positive cases
among the study subjects by Nested PCR and confirmed
by microscopy and sequenced data, the Duffy genotype
of the 13 subjects with either P. vivax single or mixed
infections was investigated. The 224 bp DARC gene
promoter fragment was successfully amplified in all the
samples. Each subjects’ DARC promoter DNA sequence
interrogated with in siliso StyI restriction enzyme showed
that StyI cut the Duffy positive promoter DNA sequence
at two sites, producing three fragments of 82, 77 andtest
P. falciparum+ P. vivax
in parenthesis* Percent fraction of total samples shown in parenthesis*
11 (4.1)
howing single, mixed infection as detected by MSP/CSP antibody card assay. A
Figure 2 A typical electrophoregram showing Plasmodium species banding patterns after the Nest 2 reaction. In this experiment, a
master mix was prepared to amplify Plasmodium DNA in all the samples in the Nest 1 reaction. After the Nest 2 amplification protocol, the
amplicons were then separated on a 2% agarose gel (see methods for more details). M = 100 bp Ladder, F = P. falciparum, V = P. vivax, M = P.
malariae, O = P. ovale. –ve ctrl = Negative control (MiliQ water), Pf + ve = P. falciparum positive control DNA, Pv + ve = P. vivax positive control DNA,
BK095 & BK010 are 2 subjects’ samples.
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DNA sequence was cut additionally at a site created by
the T→C point mutation in the 77 bp fragment, thereby
producing 4 fragments of 82, 12, 65, and 64 bp (Figure 4).
Multiple sequence alignment of the sequenced DARC
promoter gene fragments for 12 of the 13 assessed sub-
jects; alongside a Duffy positive consensus sequence
showed the T→C point mutation which confers the
Duffy negative phenotype (Figure 5). This established the
prevalence of Duffy positive individuals in the present
investigation at 50% (6/12). One case was lost and could
not be analysed.
Discussion
Detection of malaria parasites in asymptomatic
populations
Three methods, namely Giemsa staining, antibodies and
PCR, were used to detect parasites in asymptomatic indi-
viduals. The overall prevalence of anti-parasite antibodiesTable 2 Mono and multiple infecting Plasmodium species
in the studied subjects by PCR





Pf + Pv 1.1 (3/269)
Pf + Pm 1.5 (4/269)
Pf + Pv + Pm 0.4 (1/269)
Pf = P. falciparum; Pv = P. vivax; Pm = P. malariae.was relatively high (72.1%) but this largely reflected the
fact that subjects were constantly exposed to infective
bites of mosquitoes or sustained an immune response
after active infection. Nonetheless this test and Giemsa
gave the first clue that the study subjects may be infected
with P. vivax parasites. However PCR clearly established
that about a third of the study population was infected
with malaria parasites. This suggests an unexpectedly high
level of asymptomatic infection. Further a substantial por-
tions of infections (~15%) contained P. vivax. Nonetheless
this was lower than the 33.3% prevalence of microscopic-
ally diagnosed “P. vivax-like” infection described by Kimbi
et al. [20]. It was surprising that P. ovale failed to be
detected, since other reports in the area that have docu-
mented the presence of P.ovale [20,22,38]. As follow-up of
the findings in the present study, the wider existence of
P. vivax in Bolifamba and Cameroon should be further
ascertained.
Plasmodium vivax in Africa
The present report documents the first substantiated
evidence of P. vivax infection in Cameroonian Bolifamba
residents, in the SWR of Cameroon, raising the number of
infecting human Plasmodium species in Cameroonians to
four. There have been other reports of P. vivax elsewhere
on the African continent where P. vivax was initially
thought to be non-existent or that the population was
refractory to infection. These countries include Angola
[6], Equatorial Guinea [6,7], Madagascar [8], Mauritania
[9], Sudan [10], Kenya [11], Sao Tomé and Principe
[12-15], Congo [14], Mali [16], and Ethiopia [17]. Al-
though the exact prevalence data for P. vivax in Africa is
Figure 3 BLASTn output of the sequences generated from the triple Plasmodium infected subject. Here, each of the sequences was
queried against the Plasmodium GeneBank data and number of hits with percentages identities displayed. For the three sequences, the Gene
Bank ID of the reference sequences are shown in blue starting with “gb” for GeneBank.
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countries where many Duffy positive people are perman-
ent residents [8,9,11]. However, the Duffy negative status
has been plausibly shown not to be a barrier to P. vivax
infection as previously believed [8] and confirmed in
other studies [6,9], as well as the current one. The in-
creasing prevalence of P. vivax on the African continent
and its discovery in Cameroonians could be inversely
correlating to the decreasing prevalence of P. falciparum
as a result of targeted control of the latter relative to the
other malaria parasite species. A similar phenomenon hasbeen documented in Malaysia, where an increasing
incidence of P. knowlesi is being linked to the control of
P. falciparum and P. vivax [39].
The Duffy phenotype
With the notion that the Duffy antigen is necessary for
the invasion of P. vivax into red cells, the Duffy genotype
of all the subjects who were positive for P. vivax was
assessed. Six (6) of the P. vivax infected subjects were
Duffy positive (50%) and the other 6, Duffy negative.
Following the three investigative molecular approaches
Figure 4 in silico StyI restriction map for the DARC gene promoter fragment sequence. This shows sites for StyI restriction (red horizontal
bars) in two of the subjects assessed – one Duffy positive (BK122) with 2 StyI restriction sites and the other Duffy negative (BK267) with 3 StyI
restriction sites.
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P. vivax-infected individuals, two were very evident, while
one was compromised by the low power of resolution of
restriction fragments on a 20% native DNA PAG. The
report of Duffy positive Cameroonians is a new finding.
No previous study has been conducted in Cameroon to
identify and determine the prevalence of the Duffy posi-
tive phenotype or genotype because of the general belief
that Africans (Blacks) were largely or entirely Duffy nega-
tive and resistant to P. vivax infection. The findings in the
present study corroborate a series of previous reports of
the Duffy positive genotype on the African continent
where it was thought to be non-existent and therefore a
natural protecting factor for Africans against P. vivax
infection [39,40]. Recently, Mendes and colleagues [8]
showed unequivocally that the Duffy negative genotype
was no longer a barrier to P. vivax infection, with the
parasite infecting both Duffy positive and negativeFigure 5 Multiple sequence alignment of subjects’ and a Duffy positi
positive consensus sequence is highlighted in bold. The alignment point in
BK272 represent the subject sample codes. Twelve subject samples were su
Subjects BK010, BK036, BK041, BK075, BK267 and BK272 were Duffy negativ
Duffy positive.people, while others have implicated P. vivax as the
causative agent in cases of severe malaria in African
children [10,16].
The locale in Cameroon
The south-west region of Cameroon is home to Mount
Cameroon and there are several recreational and touris-
tic sites that attract individuals of various nationalities.
With the movement of people across geographic regions,
it is likely that P. vivax was introduced in Cameroon a
long time ago. The malaria vectors and parasites are
equally changing their host range and/or adapting to
new invasion strategies [29]. This is evident from the
recent observation that P. knowlesi, originally a simian
malaria species, can now infect humans [5]. A similar
adaptation of the P. vivax parasite could be occurring,
accounting for its increasing prevalence on the African
continent. It is equally likely the P. vivax species mayve consensus sequence, showing T→ C point mutation. The Duffy
dicating the T→ C point mutation is highlighted in bold. BK010 –
ccessfully aligned with the Duffy positive consensus sequence.
e, while subjects BK043, BK050, BK072, BK073, BK093 and BK122 were
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detection. The observed prevalence of 50% for the Duffy
positive antigen is relatively high and therefore cannot
be ignored despite the small sample size of P. vivax
positive subjects. The finding that both Duffy positive
and negative malaria asymptomatic Bolifamba residents
habored P. vivax parasitaemia suggests that the parasite
may have evolved and could be using novel receptors
to gain access into erythrocytes as proposed by some
research groups [6,11,41]. This idea was most conclusively
proven correct by Ménard and colleagues [8].
Conclusions
These data provide the first definitive, molecular evidence
of P. vivax and the Duffy positive and negative genotypes
in native Bolifamba residents of Cameroon. Further inves-
tigations with a larger sample to establish the prevalence
of P. vivax are appropriate. The results presented here
indicate that there may be a need for the health sector
in Cameroon to review the management of malaria to
include P. vivax.
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